Completed
Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)
NCT01840319
- Conditions
- Survival Status at Day 30 After the Last Intake
- Locations
-
- Pfizer Investigational Site Amiens, France
- Pfizer Investigational Site Marseille, France
- Pfizer Investigational Site Marseille, France
- Pfizer Investigational Site Montpellier, France